ArticleThe Pan African medical journal2024
Risk factors for rifampicin resistance tuberculosis among patients attending Directly Observed Treatments Centres in Southwestern Nigeria.
Article in The Pan African medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: tuberculosis (TB) remains a disease of global health importance. GeneXpert has emerged as a useful tool for the diagnosis of drug resistant TB (DR-TB). We determined the risk factors associated with DR-TB among presumptive pulmonary TB patients. Methods: a cross-sectional study was conducted among presumptive TB patients attending Directly Observed Treatments (DOTs) centres in Southwestern Nigeria. Sputum samples were obtained from individuals with suspected pulmonary TB, subjected to GeneXpert as the first-line test and then culture. Data were analysed using STATA 12. Results: sputum samples were collected from 2,169 consecutive patients and processed. A greater proportion of the participants (52.14%) were female, most within the age range of 20-39 (38.36%) and 40-59 (36.93%) years. About two-thirds, 66.34% (1439/2169) were GeneXpert positive and of this, 47 (3.27%) were DR-TB. Overall, 44.04% (855/2169) samples were culture positive. 7.56% of the patients were HIV positive, while 19.50%, 1.52% and 61.96% were new, relapse and previously treated cases, respectively. Multivariate analysis identified case definition (OR=2.38; 95%CI: 1.92-3.03) and (OR= 8.33; 95%CI: 5.26-12.50) and HIV (OR= 1.85; 95%CI: 1.29-2.65) and (OR= 3.61; 95%CI: 2.59-5.02) based on GeneXpert and culture as important risk factors for TB and DR-TB infection among participants. Conclusion: we found a moderate level prevalence of DR-TB with gender, previous TB treatments, and HIV status as major factors associated with DR-TB among study participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.